BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 19117347)

  • 1. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.
    Kobayashi M; Ikeda K; Kawamura Y; Yatsuji H; Hosaka T; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Kumada H
    Cancer; 2009 Feb; 115(3):571-80. PubMed ID: 19117347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.
    Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Minami Y; Ueshima K; Haji S
    Oncology; 2007; 72 Suppl 1():98-103. PubMed ID: 18087189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up.
    Waki K; Aikata H; Katamura Y; Kawaoka T; Takaki S; Hiramatsu A; Takahashi S; Toyota N; Ito K; Chayama K
    J Gastroenterol Hepatol; 2010 Mar; 25(3):597-604. PubMed ID: 20074153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
    J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma.
    Imamura H; Matsuyama Y; Miyagawa Y; Ishida K; Shimada R; Miyagawa S; Makuuchi M; Kawasaki S
    Br J Surg; 1999 Aug; 86(8):1032-8. PubMed ID: 10460639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
    Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
    Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.
    Nagaoka S; Yatsuhashi H; Hamada H; Yano K; Matsumoto T; Daikoku M; Arisawa K; Ishibashi H; Koga M; Sata M; Yano M
    Cancer; 2003 Dec; 98(12):2671-7. PubMed ID: 14669288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.
    Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Nagai T; Minami Y; Ueshima K
    Oncology; 2008; 75 Suppl 1():91-8. PubMed ID: 19092277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The comparative results of radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma].
    Cho CM; Tak WY; Kweon YO; Kim SK; Choi YH; Hwang YJ; Kim YI
    Korean J Hepatol; 2005 Mar; 11(1):59-71. PubMed ID: 15788886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The factors related to the prognosis of solitary hepatocellular carcinoma after radiofrequency ablation].
    Chung IK; Park MJ; Kwon KT; Park YD; Chung YJ; Jeon SW; Lee MK; Seo HE; Lee YD; Cho CM; Tak WY; Kweon YO; Kim SK; Choi YH
    Korean J Hepatol; 2005 Dec; 11(4):371-80. PubMed ID: 16380666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients.
    Hiraoka A; Michitaka K; Horiike N; Hidaka S; Uehara T; Ichikawa S; Hasebe A; Miyamoto Y; Ninomiya T; Sogabe I; Ishimaru Y; Kawasaki H; Koizumi Y; Hirooka M; Yamashita Y; Abe M; Hiasa Y; Matsuura B; Onji M
    J Gastroenterol Hepatol; 2010 Feb; 25(2):403-7. PubMed ID: 19929922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
    Ueno S; Sakoda M; Kubo F; Hiwatashi K; Tateno T; Baba Y; Hasegawa S; Tsubouchi H;
    J Hepatobiliary Pancreat Surg; 2009; 16(3):359-66. PubMed ID: 19300896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Taketomi A; Sanefuji K; Soejima Y; Yoshizumi T; Uhciyama H; Ikegami T; Harada N; Yamashita Y; Sugimachi K; Kayashima H; Iguchi T; Maehara Y
    Transplantation; 2009 Feb; 87(4):531-7. PubMed ID: 19307789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications.
    Hiraoka A; Horiike N; Yamashita Y; Koizumi Y; Doi K; Yamamoto Y; Hasebe A; Ichikawa S; Yano M; Miyamoto Y; Ninomiya T; Otomi Y; Kokame M; Iwamura T; Ishimaru Y; Sogabe I; Kashihara K; Nishiura S; Ootani H; Takamura K; Kawasaki H
    Hepatogastroenterology; 2008; 55(88):2171-4. PubMed ID: 19260499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.
    Raut CP; Izzo F; Marra P; Ellis LM; Vauthey JN; Cremona F; Vallone P; Mastro A; Fornage BD; Curley SA
    Ann Surg Oncol; 2005 Aug; 12(8):616-28. PubMed ID: 15965731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma.
    Ogawa C; Kudo M; Minami Y; Chung H; Kawasaki T
    Hepatogastroenterology; 2008; 55(85):1454-7. PubMed ID: 18795710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation.
    Takahashi S; Kudo M; Chung H; Inoue T; Nagashima M; Kitai S; Tatsumi C; Minami Y; Ueshima K; Fukunaga T; Haji S
    Dig Dis; 2007; 25(4):303-9. PubMed ID: 17960064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome.
    Zytoon AA; Ishii H; Murakami K; El-Kholy MR; Furuse J; El-Dorry A; El-Malah A
    Jpn J Clin Oncol; 2007 Sep; 37(9):658-72. PubMed ID: 17766723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.